Background: Criminal problem-solving courts and civil dependency courts often have participants with substance use disorder (SUD), including opioid use disorder (OUD). These courts refer participants to treatment and set treatment-related requirements for court participants to avoid incarceration or to regain custody of children. Medications for opioid use disorder (MOUD) are the most effective treatment for OUD but are underutilized by court system participants. Little is known about variation in court policies for different MOUDs. Also, more information is needed about types of policies for each MOUD, including whether participants may begin MOUD, continue previously begun MOUD, or complete the court program with MOUD. Methods: An online survey was distributed to criminal problem-solving and civil dependency judges in Florida in 2019 and 2020, yielding data from 58 judges (a 24% response rate). We used nonparametric statistics to test hypotheses with ordinal data. A Friedman's test for related samples or Cochran's Q was used to make within-group comparisons between policies and MOUDs. Results: We found considerable policy variation, with more permissive policies for naltrexone than buprenorphine or methadone, and more permissive policies for continuing MOUD than for initiating MOUD or completing a court program with MOUD. For each medication, less than one quarter of judges indicated their court always permits MOUD, with most indicating that MOUD is permitted sometimes or usually. Conclusion: Because respondents rarely chose “never” or “always” for any MOUD policy, most courts appear to be making MOUD decisions on a case-by-case basis. A clearer understanding of this decision-making process is needed. Some court participants may be required to discontinue MOUD before completing a court program, even if they were permitted to start or continue MOUD treatment. Discontinuation of MOUD without medical justification is contrary to the standard of care for individuals with OUD and increases their risk of overdose.
BaldwinJ.Veterans Treatment Courts: Studying Dissemination, Implementation, and Impact of Treatment-Oriented Criminal Courts. Gainesville, FL: University of Florida; 2013.
2.
TsaiJ, FlatleyB, KasprowWJ, ClarkS, FinlayA.Diversion of veterans with criminal justice involvement to treatment courts: participant characteristics and outcomes. Psychiatr Serv. 2017;68(4):375–383.
3.
Douglas MarloweCH, FoxC. Painting the Current Picture: A National Report on Drug Courts and Other Problem-Solving Courts in the United States. Alexandria, VA: National Drug Court Institute; 2016.
4.
Center for Children and Family Futures and National Association of Drug Court Professionals. Family Treatment Court Best Practice Standards. Center for Children and Family Futures and National Association of Drug Court Professionals; 2019. Supported by Grant #2016-DC-BX-K003 awarded by the Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, U.S. Department of Justice, Lake Forest, CA.
5.
DoddEA.Mental Health Courts: A Guide to Research-Informed Policy and Practice. New York, NY: Council of State Governments Justice Center; 2009.
6.
National Academies of Science Engineering & Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press; 2019.
7.
WakemanSE, LarochelleMR, AmeliOComparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
8.
LarochelleMR, BernsonD, LandTMedication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
9.
PotterJS, MarinoEN, HillhouseMPBuprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment with Agonist Replacement Therapies (START). J Stud Alcohol Drugs. 2013;74(4):605–613.
KrawczykN, PicherCE, FederKA, SalonerB.Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood). 2017;36(12):2046–2053.
12.
YatscoAJ, GarzaRD, Champagne-LangabeerT, LangabeerJR.Alternatives to arrest for illicit opioid use: a joint criminal justice and healthcare treatment collaboration. Subst Abuse. 2020;14:1178221820953390.
13.
FendrichM, LeBelTP.Implementing access to medication assisted treatment in a drug treatment court: correlates, consequences, and obstacles. J Offender Rehabil. 2019;58(3):178–198.
14.
FriedmannPD, HoskinsonR, GordonM,et al. Medication-assisted treatment in criminal justice agencies affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9–18.
15.
Physicians for Human Rights. Neither Justice nor Treatment: Drug Courts in the United States. New York, NY: Physicians for Human Rights; 2017.
16.
National Association of Drug Court Professionals. Adult Drug Court Best Practice Standards Volume II National Association of Drug Court Professionals. Alexandria, VA: National Association of Drug Court Professionals; 2015.
17.
Andraka-ChristouB, AtkinsDN.Whose opinion matters about medications for opioid use disorder? A cross-sectional survey of social norms among court staff. Subst Abus. 2020:1–16.
18.
MatusowH, DickmanSL, RichJDMedication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.
19.
CseteJ, CataniaH. Methadone treatment providers’ views of drug court policy and practice: a case study of New York State. Harm Reduct J. 2013;10(:35.
20.
Andraka-ChristouB.What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts. CRCL. 2017;13:189–254.
Substance Abuse and Mental Health Services Administration.Grants to Expand Substance Abuse Treatment Capacity in Adult and Family Treatment Drug Courts: Funding Opportunity Announcement (FOA) No. TI-20-003. Rockville, MD: Substance Abuse & Mental Health Services Administration; 2020.
23.
Andraka-ChristouB, AtkinsD.Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff. Am J Drug Alcohol Abuse. 2020;46(6):749–760.
24.
Andraka-ChristouB, GabrielM, MadeiraJ, SilvermanRD.Court personnel attitudes towards medication-assisted treatment: a state-wide survey. Journal of Substance Abuse Treatment. 2019;104:72–82.
25.
Smith v. Aroostook, No. 1:18-cv-352-NT (D. Me. Mar. 27, 2019).
26.
Smith v. Aroostook, No. 1:18 cv 352 NT (D. Me. Mar. 27, 2019), aff'd, No. 19 1340, (1st Cir. Apr. 30).
MorganJR, SchackmanBR, LeffJA, LinasBP, WalleyAY.Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96.
29.
SullivanMA, BisagaA, PavlicovaMA randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176(2):129–137.
30.
WillisGB.Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks, CA: Sage Publications; 2005.
31.
Andraka-ChristouB, AtkinsD, MadeiraJ, SilvermanRD.Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: a preliminary study of Florida criminal problem-solving and dependency court staff. Drug Alcohol Rev. 2020;39(5):583–587.
32.
SloanFA, GiffordEJ, EldredLM, AcquahKF, BlevinsCE.Do specialty courts achieve better outcomes for children in foster care than general courts?Eval Rev. 2013;37(1):3–34.
33.
Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Full Document. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
34.
FiellinDA, MooreBA, SullivanLE,et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–120.
35.
Lo-CiganicWH, DonohueJM, KimJYAdherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States. Pharmacoepidemiol Drug Saf. 2019;28(1):80–89.
36.
Lo-CiganicWH, GelladWF, GordonAJAssociation between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.
National Association of Drug Court Professionals.Adult Drug Court Best Practice Standards Volume I Text Revision. Alexandria, VA: National Association of Drug Court Professionals; 2018.
39.
Champagne-LangabeerT, SwankMW, LangabeerJR.2nd.Routes of non-traditional entry into buprenorphine treatment programs. Subst Abuse Treat Prev Policy. 2020;15(1):6.
40.
HannaJ, KubiakS, PasmanEEvaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: application of the consolidated framework for implementation research in a cross-system initiative. J Subst Abuse Treat. 2020;108:104–101.
41.
GreenTC, ClarkeJ, Brinkley-RubinsteinLPostincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–403.
42.
MitchellSG, WilletJ, MonicoLBCommunity correctional agents’ views of medication-assisted treatment: examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016;37(1):127–133.
43.
McKenzieMN, ZallerN, BazaziA, RichJ.Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag. 2010;5:219–227.
44.
FriedmannPD, WilsonD, KnudsenHKEffect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015;50:50–58.
